home / stock / ikt / ikt news

IKT News and Press, Inhibikase Therapeutics Inc. From 03/07/24

Stock Information
Company Name: Inhibikase Therapeutics Inc.
Stock Symbol: IKT
Market: NASDAQ
Website: inhibikase.com
Menu
IKT IKT Quote IKT Short IKT News IKT Articles IKT Message Board
Get IKT Alerts

News, Short Squeeze, Breakout and More Instantly...
IKT - Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkins...
IKT - Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...

IKT - Tenax Therapeutics, Equillium among healthcare movers

2024-02-07 10:00:01 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

IKT - FUBO, CHEA and HUBC among pre-market losers

2024-02-07 08:22:27 ET Losers: Snap ( SNAP ) -30% after Q4 earnings release . Triumph Group ( TGI ) -19% after Q3 earnings release . MeridianLink ( MLNK ) -14% announces secondary offering of 6.5M shares . fuboTV ( FUBO ) -14% . ...
IKT - Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

BOSTON and ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...

IKT - Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD medications BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, I...

IKT - CRBP, VERA and IKT among mid-day movers

2024-01-26 12:32:20 ET Gainers: Corbus Pharmaceuticals Holdings ( CRBP ) +300% . Aclarion ( ACON ) +66% . Panbela Therapeutics ( PBLA ) +36% . Inspire Veterinary Partners ( IVP ) +36% . Rail Vision Ltd ( RVSN ) +34% . Appfoli...
IKT - Inhibikase Therapeutics appoints Lees-Rolfe as CFO

2024-01-17 03:01:33 ET More on Inhibikase Therapeutics Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historical earnings data for Inhibikase Therapeutics Financial information for Inhibikase Therapeutics For further details see: Inhibikas...

IKT - Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

BOSTON and ATLANTA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...

IKT - Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and...
Previous 10 Next 10